Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020

Lutz Naehrich a,b, Annalisa Orenti b,c, Fiona Dunlevy c-e, Irena Kasmi d, Satenik Harutyunyan e, Andreas Pfleger f, Svetlana Keegan g,h, Guergana Petrova i, Duška Tješić-Drinković j, Panayiotis Yiallouros k, Alena Bilkova l, Hanne Vebert Olesen m, Pierre-Régis Burgel n, Tsitsino Parulava o, Filia Diamantapa p, Andrea Páníčkzy q,r, Edward F McKone s, Meir Mei-Zahav t, Marco Salvatore u, Carla Colombo ax, Elina Aleksejeva v, Kestutis Malakauskas w, Marc Schlessor x, Stojka Fustik y, Oxana Turcu z, Domenique Zomer-van Ommen ab, Anita Senstad Watthe ac, Lukasz Woźniacki ad, Luísa Pereira ae, Liviu Pop af, Nataliya Kashirskaya ag, Milan Rodić ah, Hana Kayserova ai, Uro Krivcak aj, Pedro Mondejar-Lopez ak, Isabelle de Monestrol al, Deniz Dogru am, Halyana Makuk bm, Rebecca Cosgriff-an Silke van Koningsbruggen-Rietschel ao, Andreas Jung ap,q,r, European Cystic Fibrosis COVID project group, Vladimir Bobrovnic? ba, Ivan Bambir bb, Andrea Dugac Vukic bc, Pavel Drevinek bd, Milan Macek Jr bd, Harriet Corvel be, Lydie Lemonnier-Videau bf, Elpis Hatzigorou bg, Godfrey Fletcher bh, Rita Padoan bi, Vincent Gulmans bj, Egil Bakkeheim bk, Elena Kondratyeva bl, Elena Amelina bk, Elena Zhekaite bm, Olga Simonova bn, Maria Dolores Pastor-Vivero bo, Anders Lindblad bp, Yasemin Gökdemir bq, Sevgi Pekcan br, Keith Brownlee bs, Eliott McClenaghan bs, Siobhán Carr bt, Elise Lammertyn bu, Anna Zolin bv, Alice Fox bw, Marko Krasnyk bx, Jacqui Van Rens bw

b Belarusian Republic Children’s Center of Pulmonology and Cystic Fibrosis, Pulmonary Department, 3rd City Children’s Clinical Hospital, Minsk, Belarus
b University Hospital Centre Zagreb, Cystic Fibrosis Centre - Paediatrics and Adults, Zagreb, Croatia
b Department of Medical Microbiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
b Department of Biotechnology and Medical Genetics, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
b Sorbonne Université, Centre de Recherche Saint-Antoine, Inserm UMR_S938, Assistance Publique-Hôpitaux de Paris, Hôpital Trousseau, Pediatric Pulmonology Department and Cystic Fibrosis Center, Paris, France
b Vaincre la Mucoviscidose, Paris, France
b Cystic Fibrosis Unit, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
b The Cystic Fibrosis Registry of Ireland, Dublin, Ireland
b Cystic Fibrosis Regional Support Centre, Department of Paediatrics, University of Brescia, Brescia, Italy
b Dutch Cystic Fibrosis Foundation (NCTF), Baarn, The Netherlands
b Norwegian Resource Centre for Cystic Fibrosis, Oslo University Hospital, Oslo, Norway
b Clinical research department of cystic fibrosis “Research Centre for Medical Genetics”, Moscow, Russian Federation
b Cystic Fibrosis Department, Pulmonology Research Institute of the Federal Medical and Biological Agency of Russia, Moscow, Russian Federation
b Center for rare disease National Medical Research Center for Children’s Health, Moscow, Russia; Morozov State Pediatric Teaching Hospital, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia, Moscow, Russian Federation
b Pediatric Pneumology and Cystic Fibrosis Unit, Osakidetza, Hospital Universitario Cruces, Bizkaia, Spain
b Gothenburg CF Centre, Queen Silvia Children’s Hospital, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
b Division of Pulmonology, Marmara University Faculty of Medicine, Istanbul, Turkey
b Division of Pediatric Pulmonology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey
b Cystic Fibrosis Trust, London, UK
b Sciensano, Epidemiology and public health, Health services research, Brussels, Belgium
b Cystic Fibrosis Europe, Brussels; Association Muco A.S.B.L. – Mucovereniging VZW, Brussels, Belgium
b Department of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Epidemiology and Biometry G. A. Maccaro, University of Milan, Milan, Italy
b European Cystic Fibrosis Society Patient Registry, Karup, Denmark
b Universities of Giessen and Marburg Lung Center, German Center of Lung Research, Justus-Liebig-University Giessen, Giessen, Germany
b Department of Clinical Sciences and Community Health, Laboratory of Medical Statistics, Epidemiology and Biometry G. A. Maccaro, University of Milan, Milan, Italy
b European Cystic Fibrosis Society, Karup, Denmark
b “Mother Thereza” Hospital Center, Department of Pneumatology, Tirana, Albania
b Yemen University CF Centre, Mutran Hospital, Yemen, Armenia
b Department of Pediatrics and Adolescent Medicine, Division of Pediatric Pulmonology and Allergology, Medical University of Graz, Graz, Austria

* Contributed equally as first author
** Contributed equally as last author

https://doi.org/10.1016/j.jcf.2021.03.017
1569-1993/© 2021 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
ARTICLE INFO

Article history:
Received 10 February 2021
Revised 17 March 2021
Accepted 24 March 2021
Available online 18 April 2021

Keywords:
Cystic fibrosis
COVID-19
SARS-CoV-2
Europe
Incidence
Epidemiology

ABSTRACT

Background: Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF).

Methods: We used the 38-country European Cystic Fibrosis Society Patient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection.

Results: Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/1000 pwCF. Incidence was higher in lung-transplanted patients (n=23) versus non-transplanted patients (n=107) (8.43 versus 2.36 cases/1000). Incidence was higher in pwCF versus the age-matched general population in the age groups <15, 15-24, and 25-49 years (p<0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant.

Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p=0.133).

Conclusions: SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination.

© 2021 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
1. Background

SARS-CoV-2, the novel Severe Acute Respiratory Syndrome Coronavirus 2 causing Covid-19, was declared a pandemic in March 2020 by the World Health Organization (WHO). Western Europe was heavily affected in the first half of 2020. Covid-19 morbidity and mortality are highest in the elderly and in people with underlying chronic illnesses [1].

Cystic fibrosis (CF) arises from gene mutations in cystic fibrosis transmembrane conductance regulator (CFTR), which lead to chronic CF lung disease and compromised function of multiple other organ systems. Repeated cycles of respiratory infection and chronic inflammation cause progressive lung function decline. Pulmonary exacerbations can be triggered by infection with viruses such as influenza [2]. The 2009-2010 H1N1 pandemic caused significant morbidity in people with CF (pwCF) [3]. Therefore, the SARS-CoV-2 pandemic caused considerable anxiety in the CF community [4]. Early case series of pwCF in various regions who tested positive for SARS-CoV-2 suggest that pwCF have better outcomes than expected [5-8].

We aimed to assess the incidence, clinical course and outcome of SARS-CoV-2 infection in pwCF versus the general population from February to June 2020 in countries that report data to the European Cystic Fibrosis Society Patient Registry (ECFSPR).

2. Methods

2.1. Study design

This observational study was nested within the ECFSPR. We collected case reports for pwCF diagnosed with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection between 01 February 2020 and 30 June 2020, with data follow-up until 07 January 2021. Case definitions were based on WHO guidance [9-11].

ECFSPR’s 38 member countries provided data under existing ethical approvals and data governance structures. Most countries contributed data directly to ECFSPR. Belgium, France, Germany and the UK contributed via their national registries. Italy contributed via their national registry and the Italian CF society. Turkey contributed via their national registry and directly to ECFSPR. No cases were doubly reported from Italy or Turkey. ECFSPR covers 35-99% of the CF population per country [12]; 9 countries have coverage <80% (Armenia, Belarus, Bulgaria, Lithuania, Poland, Romania, Spain, Turkey and Ukraine) [12] in 2018.

The ECFSPR structure and operations have been previously described [13] (www.ecfs.eu/ecfspr). Participating pwCF provide written informed consent, including consent to use their data for future research. This provided the framework for collecting data regarding SARS-CoV-2 infection, as confirmed in writing by the ECFSPR data protection officer.

2.2. Data collected

A case report form, developed collaboratively within ECFS, was used to collect anonymized data about demographics, pre-infection CF characteristics (medical history data taken pre-infection or from 2019 registry data) and SARS-CoV-2 infection (symptoms, treatment, complications, and outcomes). Most national registries collected data in a different format, then shared a core dataset of patient-level data. One national registry shared aggregated data.

The CF population seen in the calendar year per country was from the most recent ECFSPR report (2018) [12] (and the 2017 report for France). Country-specific SARS-CoV-2 aggregate data up to 30 June 2020 for the general population (cases, deaths, hospitalizations and intensive care admissions) were from the European Centre for Disease Prevention and Control (ECDC) [14-16]. General population data were only available by different age groups for incidence (<15, 15-24, 25-49, 50-64, 65-79, >80 years) and hospitalization/ICU (0-9, 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79, >80 years). Incidence by age group was available only for a subset of 24 countries: Austria, Belgium, Croatia, Czech Republic, Cyprus, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden. Hospitalization/ICU data were available for a different subset of 30 countries (the 24 countries above plus Bulgaria, Estonia, Finland, Iceland, Malta, United Kingdom) [14]. Of note, pwCF are included in these data reported for the general European population.

2.3. Statistics

Standard ECFSPR definitions applied to all variables (www.ecfs.eu/projects/ecfs-patient-registry/Variables-Definitions). Percent predicted forced expiratory volume was calculated using Global Lung Initiative reference values [17]. Patient-level data were summarized, then aggregate data were added where available. Continuous data were categorized and presented as number and percentage (computed excluding missing data).

Clinical and demographic characteristics of pwCF with SARS-CoV-2 infection (and the subgroups of non-lung-transplanted and lung-transplanted pwCF) are reported using descriptive statistics. SARS-CoV-2 incidence was estimated in pwCF, and by country and age group, 95% confidence intervals (CIs) were computed using bimomial exact distribution. Age-specific SARS-CoV-2 incidence rates were compared in pwCF versus the general population in corresponding countries, using the exact bimomial test and p-values are provided [18]. P-values below 0.05 were considered statistically significant.

ECFSPR statisticians analyzed data using SAS (v9.4, SAS Institute Inc., Cary, NC, USA) and R v4.0. Maps were produced using www.datawrapper.de.

3. Results

3.1. Participation and patient characteristics

Of the 38 ECFSPR member countries, 22 reported zero known cases and 16 reported 130 PCR-confirmed cases up to 30 June 2020 (Fig. 1). We also received notification of 31 patients seropositive for SARS-CoV-2 but without confirmatory PCR. We excluded these patients from analyses.

Of the 130 pwCF with SARS-CoV-2 infection, 72 (55.4%) were male and 39 (30.0%) were aged <18 years. Demographics and pre-infection disease characteristics are presented by pwCF with lung transplant (n=23) and without (n=107, including 1 patient with a liver transplant) (Table 1). Compared to those without transplant, lung-transplanted pwCF were older, had higher pre-infection BMI, higher lung function, more frequent CF-related diabetes (CFRD) and pancreatic insufficiency and lower use of CFTR modulators. Lung-transplanted pwCF more frequently used azithromycin maintenance therapy (although data were often missing for this variable).

3.2. Symptoms of SARS-CoV-2 infection in pwCF

We had data about at least one symptom for 128 pwCF, but data collection was not uniform across all countries. Of the 128 pwCF with partial data available, 101 pwCF (78.9%) had symptoms of SARS-CoV-2 infection, while 27 (21.1%) were asymptomatic. Lung-transplanted pwCF had a higher rate of symptomatic SARS-CoV-2 than non-lung transplanted pwCF (91.3% versus 76.2%). PwCF most commonly reported general symptoms (≥1 event of
fever, fatigue, headache, arthralgia/myalgia) (84/122 [68.9%] with information about these symptoms), followed by pulmonary symptoms (66/112; 58.9%) (≥1 event of increased cough, dyspnea, chest tightness, wheezing, sputum production, hemoptysis).

3.3. Incidence of SARS-CoV-2 infection in pwCF

The incidence of PCR-confirmed SARS-CoV-2 in pwCF (2.70 cases per 1000; 95% CI: 2.25-3.20) was not statistically different to that of the general population (3.10/1000; 95% CI: 3.10-3.11) of the entire 38-country ECFSPR area in the same period. SARS-CoV-2 infections were concentrated in Western Europe both in pwCF and the general population (Fig. 2), although this could be due to differing rates of testing between countries. Incidence per 1000 pwCF by country varied from 1.11 to 7.26, with large confidence intervals for all countries (Supplementary Table 1).

SARS-CoV-2 incidence was significantly higher in lung-transplanted pwCF (8.43/1000, 95% CI: 5.35-12.62) versus non-lung-transplanted pwCF (2.36/1000, 95% CI: 1.94-2.86).

When incidence was considered by age group for the 24 countries with data for both populations, SARS-CoV-2 incidence was significantly higher in pwCF versus the general population for those aged <15, 15-24, and 25-49 years (p<0.001). This pattern was maintained when incidence by age group was considered for pwCF with and without lung transplant (Fig. 3, Supplementary Table 2).

3.4. Management and outcomes

Overall, 75 pwCF (58.1%) were admitted to hospital and 12 (9.2%) to intensive care (Table 2). Lung-transplanted pwCF had higher rates than non-lung-transplanted pwCF of hospital (82.6% versus 52.8%) and intensive care (26.1% versus 5.6%) admission (Fig. 3, Supplementary Tables 4 and 5).

Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data. Importantly, this pattern of higher hospitalization rates in pwCF was maintained even when we excluded pwCF lung transplant from the analysis (Fig. 3, Supplementary Table 4).

The rate of intensive care admissions was notably higher in pwCF versus the general population. Some differences were observed by age group when pwCF with and without lung transplant were compared versus the general population (Fig. 3, Supplementary Table 5), but low numbers in some subgroups prevent robust comparisons.

PwCF with SARS-CoV-2 infection were most commonly treated with additional intravenous antibiotics (49.5%) and additional oral antibiotics (36.8%) (Supplementary Table 3).

Oxygen was administered to 24/86 (27.9%) pwCF and 10/80 (12.5%) received some form of respiratory support. Five pwCF received non-invasive ventilation, 5 required invasive ventilation and 2 had an additional extracorporeal membrane oxygenation (ECMO). Most pwCF recovered (96.2%), however 5 (3.8%) died.

Of the 5 pwCF who died, 3 had received a lung transplant and 2 did not. Complete case information was available for 3 of the 5 patients who died. All 3 patients had general and pulmonary symptoms of SARS-CoV-2 infection. They were all F508del homozygous lung transplant recipients with pancreatic insufficiency and aged over 20 years at the time of SARS-CoV-2 infection. Two had CFRD. All 3 had invasive ventilation in intensive care (2 of whom required ECMO) and 2 received treatment with steroids.

Case fatality rates were calculated for pwCF and the general population of the 16 countries with SARS-CoV-2 cases in both pop-
Table 1
Demographics and pre-infection characteristics of people with cystic fibrosis with SARS-CoV-2.

| Age, years, n (%) | Total N=130 | Non-lung transplant N=107 | Lung-transplant N=23 |
|-------------------|-------------|--------------------------|---------------------|
| 0-11              | 15 (11.5%)  | 15 (14%)                 | 0 (0%)              |
| 12-17             | 24 (18.5%)  | 24 (22.4%)               | 0 (0%)              |
| 18-29             | 37 (28.5%)  | 33 (30.8%)               | 4 (17.4%)           |
| 30-49             | 49 (37.7%)  | 30 (28%)                 | 19 (82.6%)          |
| 50+               | 5 (3.8%)    | 5 (4.7%)                 | 0 (0%)              |
| Sex, n (%)        |             |                          |                     |
| Female            | 58 (44.6%)  | 50 (46.7%)               | 8 (34.8%)           |
| Male              | 72 (55.4%)  | 57 (53.3%)               | 15 (65.2%)          |
| Genotype, n (%)   |             |                          |                     |
| F508del homozygous| 57 (43.8%)  | 45 (42.1%)               | 2 (8.7%)            |
| F508del heterozygous| 46 (35.4%) | 37 (34.6%)               | 9 (39.1%)           |
| Other             | 27 (20.8%)  | 25 (23.4%)               | 12 (52.2%)          |
| Unknown           | 0           | 0                        | 0                   |
| BMI, kg/m², n (%) |             |                          |                     |
| <18.5             | 31 (26.3%)  | 27 (28.1%)               | 4 (18.2%)           |
| 18.5-30           | 82 (69.5%)  | 64 (66.7%)               | 18 (81.8%)          |
| >30               | 5 (4.2%)    | 5 (5.2%)                 | 0 (0%)              |
| Unknown           | 8           | 7                        | 1                   |
| Azithromycin (maintenance therapy pre-infection), n (%) | | | |
| Yes               | 30 (39.0%)  | 23 (35.4%)               | 7 (58.3%)           |
| No                | 47 (61.0%)  | 42 (64.6%)               | 5 (41.7%)           |
| Unknown           | 53          | 42                       | 11                  |
| ppFEV₁, n (%)     |             |                          |                     |
| ≤40%              | 31 (26.5%)  | 27 (28.4%)               | 4 (18.2%)           |
| 41-70%            | 31 (26.5%)  | 28 (29.5%)               | 3 (13.6%)           |
| >70%              | 55 (47.0%)  | 40 (42.1%)               | 15 (68.2%)          |
| Unknown           | 5           | 4                        | 1                   |
| Pseudomonas aeruginosa, n (%) | | | |
| Yes               | 65 (51.2%)  | 53 (50.5%)               | 12 (54.5%)          |
| No                | 62 (48.8%)  | 52 (49.5%)               | 10 (45.5%)          |
| Unknown           | 3           | 2                        | 1                   |
| CF related diabetes, n (%) | | | |
| Yes               | 40 (32.0%)  | 26 (25.2%)               | 14 (63.6%)          |
| No                | 85 (68.0%)  | 77 (74.8%)               | 8 (36.4%)           |
| Unknown           | 5           | 4                        | 1                   |
| Pancreatic insufficiency, n (%) | | | |
| Yes               | 82 (65.2%)  | 75 (76.6%)               | 19 (82.6%)          |
| No                | 21 (20.4%)  | 20 (24.4%)               | 1 (13.6%)           |
| Unknown           | 27          | 25                       | 2                   |
| CFTR modulator therapy, n (%) | | | |
| Yes               | 31 (24.6%)  | 30 (29.1%)               | 1 (3.8%)            |
| No                | 95 (75.4%)  | 73 (70.9%)               | 22 (95.7%)          |
| Unknown           | 4           | 4                        | 0                   |

Abbreviations: BMI=body mass index, CFTR=cystic fibrosis transmembrane conductance regulator, ppFEV₁=percent predicted forced expiratory volume in one second
Percentages are calculated based on non-missing data.
1This group included 1 patient with a liver transplant
2BMI was only calculated for patients aged 2 years and older. Data were not available to calculate z-scores.
3Percent predicted FEV₁ was only calculated for patients not lung transplanted and aged 6 years and older.
4In the last 12 months.

Table 2
Outcome of SARS-CoV-2 infection in people with cystic fibrosis, by lung transplant status.

|                  | Total (N=130) | Non-lung transplant N=107 | Lung-transplant N=23 |
|------------------|---------------|---------------------------|----------------------|
| Hospital admission|               |                           |                      |
| Yes              | 75 (58.1%)    | 56 (52.8%)                | 19 (82.6%)           |
| No               | 54 (41.9%)    | 50 (47.2%)                | 4 (17.4%)            |
| Missing          | 1             | 1                         | 0                    |
| Intensive care unit|              |                           |                      |
| Yes              | 12 (9.2%)     | 6 (5.6%)                  | 6 (26.1%)            |
| No               | 118 (90.8%)   | 101 (94.4%)               | 17 (73.9%)           |
| Missing          | 0             | 0                         | 0                    |
| Death            |               |                           |                      |
| Yes              | 5 (3.8%)      | 2 (1.9%)                  | 3 (13%)              |
| No               | 125 (96.2%)   | 105 (98.1%)               | 20 (87%)             |
| Missing          | 0             | 0                         | 0                    |

Abbreviations: SARS-CoV-2=Severe Acute Respiratory Syndrome Coronavirus 2
Percentages are calculated based on non-missing data
The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; 95% CI: 7.43-7.49; p=0.133).

**Discussion**

We used the 38-country ECFSPR framework to collect case data about PCR-confirmed SARS-CoV-2 infection in pwCF. Up to 30 June 2020 we report that incidence was significantly higher in pwCF versus the age-matched general population, where comparisons could be made. PwCF had significantly higher rates of hospitalization, even when lung-transplanted pwCF were excluded and notably higher rates of intensive care admissions.

In the ECFSPR geographic area, the overall incidence of SARS-CoV-2 in pwCF was not significantly different to the incidence of that of the corresponding general population (2.70 versus 3.10/1000). SARS-CoV-2 was lower in pwCF versus the general population in studies from a global group (0.7/1000 versus 1.5/1000 up to mid-April 2020) [7], Spain (3.2/1000 versus 4.9/1000 up to 16 May 20) [18], France (4.1/1000 pwCF up to 30 June 20) [5], Italy (15.8/1000 versus 29.1/1000 up to November 2020) [20] and Verona, Italy (1.9/1000 versus 4/1000 up to 23 July 20) [21].

However, age represents a major confounding factor to these comparisons of incidence, due to different age distributions in pwCF versus the general population. PwCF have a shorter lifespan than the general population, with a median age of survival in the range of 40-55 years and the median age at death of 31.2 years [22]. We addressed this confounder with subgroup analysis of incidence by age group and found that SARS-Co-V2 incidence was significantly higher in pwCF versus the general population for all age groups up to 49 years of age (p<0.001). According to the 2018 ECFSPR report, 96% of pwCF are aged below 50 years [12]. Therefore, for the vast majority of the European CF population, incidence of SARS-CoV-2 is significantly higher than in the age-matched general population.

Several caveats exist for incidence estimates. First, testing in early 2020 was restricted to symptomatic cases with usual respiratory symptoms, therefore many cases of asymptomatic or mild infections probably went undetected, both in pwCF and the general population. ECDC data show that the rate of testing for SARS-CoV-2 increased steadily throughout the reported period and varied widely between countries [23]. Second, cases could have been under-reported by overwhelmed hospital teams. Third, pwCF may have been tested more frequently than the general population due to increased vigilance and established care routines, particularly for younger age groups. Testing rates by age group are not available from the ECDC. Conversely, we also know that many CF teams switched to conducting care and clinical trial visits remotely as much as possible to minimize the risk of exposure [19, 24] which could have led to missed opportunities to test asymptomatic and mildly ill pwCF for SARS-CoV-2 infection. Fourth, comparing incidence by country (either in our study or in other published reports) is difficult due to differing impacts of the pandemic, case definitions and public health measures between countries. Fifth, pwCF and their families are expert in infection control. Anecdotal evidence suggests that they took early action to avoid infection and effectively started lockdown or shielding earlier than it was imposed in countries across Europe to proactively avoid infection [25]. Sixth, we do not know details about the type of PCR tests.
used to diagnosis SARS-CoV-2 infection in pwCF across the different countries. PCR tests vary in brand, sensitivity and the platform used [26]. Given these caveats, the true incidence in pwCF will only become apparent with large scale, comprehensive and timely serological studies.

Nonetheless, our data show the importance that pwCF continue to protect themselves from infection by maintaining good lung health (via exercise, physiotherapy and medical treatment) and by shielding, reducing social contacts, wearing a mask and maintaining high standards of hand hygiene.

4.1. Disease course and outcomes

SARS-CoV-2 caused symptomatic illness in 101/128 (78.9%) of our cohort, where data about symptoms were available, lower than the 82-100% reported in other studies in CF [5, 7, 19] but comparable to the reported rate of symptomatic illness in the general population in the first half of 2020 (80%) [27]. In our cohort of pwCF, the most common symptoms were general or pulmonary, in line with symptoms commonly experienced by the general population. Just over half of pwCF with SARS-CoV-2 were admitted to hospital and 9.2% were admitted to intensive care. pwCF were more frequently admitted to hospital and intensive care than the general population in all age groups up to 49 years (after which age too few cases in pwCF are available for robust comparison). The use of hospitalization as a proxy for severe Covid-19 should be interpreted with caution, as hospitalization could have been precautionary, or for reasons other than Covid-19. Of note, a meta-analysis has identified male sex as a risk factor for death and intensive care admission in the general population [28]. It is therefore possible that the over-representation of male pwCF in our cohort (55.4%) could have partly driven rates of intensive care.

The case fatality rate in pwCF was lower (but not significantly) than the general population (3.85% vs 7.46%, p=0.133). More data is required to confirm this, and to untangle whether this could be due to the younger age and/or the absence of other risk factors for more severe course of the infection in our cohort of pwCF with SARS-CoV-2, or the heterogeneous testing and reporting between countries.

People with solid organ transplants have an increased risk of severe disease from SARS-CoV-2 infection [29]. ECFSPR 2018 data report that 1816 pwCF (4.4% of the ECFSPR population) were living with a lung transplant [12], representing a large group at risk for severe complications if infected with SARS-CoV-2. Our cohort included 23 pwCF with lung transplant. Upon SARS-CoV-2 infection, lung-transplanted pwCF were more frequently symptomatic, were admitted to hospital 1.7-fold more frequently and required intensive care 8-fold more frequently than pwCF without lung transplant. Previous studies also found that solid organ transplant recipients require more treatment and medical care upon SARS-CoV-2 infection, whether transplant was for CF [5, 7] or other reasons [30, 31].

4.2. Limitations and future directions

Our study had several limitations, as well as the caveats related to testing and incidence discussed above. Throughout the study period, countries had differing impact of the pandemic and heterogeneous access to testing. Case definitions were also heterogeneous between countries, as reflected in the different case definitions in published studies in CF [5, 7, 19, 21]. Reporting to ECFSPR was vol-
unitary, therefore cases may be under-reported with possible selection bias for more severe cases. In addition, ECFSPR has low coverage in some countries, especially in Eastern Europe [12]. Since these countries reported a low incidence of SARS-CoV-2 in the general population during our study period, we do not believe this to be problematic. However, it could however skew future updates of incidence, as SARS-CoV-2 cases have risen significantly in these countries since summer 2020, whether through increased testing or increased impact of the pandemic. The denominator for calculating SARS-CoV-2 incidence in pwCF was from the 2018 ECFSPR report. It is possible that the CF population has increased since then. In some countries and regions, lung transplanted pwCF are treated by another care team or at another hospital. Therefore, it is possible that some lung-transplanted pwCF no longer participate in ECFSPR and the number of infections in pwCF living with a transplant could be under-reported here. Of note, pwCF from 11 countries in our study were also included in the global study [7] and in national or center-based studies [5, 19, 21, 32] in pwCF.

We sourced comparator data for the general population from the ECDC and included only pwCF with PCR-confirmed SARS-CoV-2 to facilitate comparisons. However, ECDC datasets were limited to certain subsets of countries and age groups, forcing us to exclude some cases in pwCF from comparisons.

Finally, some comparisons reported here should be interpreted with caution due to low sample sizes, particularly in subgroup analyses. We are currently enlarging our dataset by collecting cases up to the end of 2020. This will increase the robustness of our analyses and will facilitate multivariate analyses to identify risk factors associated with severe disease and worse outcomes. We also plan to assess the long-term effect of SARS-CoV-2 infection on lung function and pulmonary exacerbations in pwCF, as well any effects of concomitant CFTR modulator therapy. This is important since pulmonary exacerbation and lung function decline have been previously associated with viral infection by H1N1 [3], RSV [2] and influenza B [33].

5. Conclusion

Since the case cutoff of 30 June 2020 in this study, the number of cases has risen significantly, with expansion into Eastern Europe (1126 cases reported up to 08 March 2021, www.ecfs.eu). At the time of writing, several vaccines have been approved by the EMA and vaccination campaigns have started. Here we show that, versus the age-matched general population, pwCF have a higher incidence of SARS-CoV-2 infection and hospitalization, especially lung-transplanted pwCF. Although more data are required to confirm these findings, it is clear that SARS-CoV-2 infection can result in severe illness and death for pwCF, especially for those with lung transplants. PwCF should continue to protect their health by shielding and maintaining good adherence to treatments and exercise. Governments should prioritize pwCF of all ages for vaccination, by listing CF as an underlying condition with an increased risk of more severe disease.

Contributors

Belgium

Hedwige Boboli, Department of Pediatrics, Pediatric Pulmonology, University Hospital Liège, Liège, Belgium.
Elke De Wachter, Department of Paediatric Pulmonology, Universitair ziekenhuis Brussel, Brussels, Belgium.
Lieven Dupont, Department of Pneumology, University Hospitals Leuven, Leuven, Belgium.

Sophie Gohy, Department of Pulmonology Cliniques Universitaires Saint-Luc UCL, Brussels, Belgium & Cystic Fibrosis Reference Center Cliniques Universitaires Saint-Luc UCL, Brussels, Belgium.
Laurence Hanssens, CF centre, Hôpital Universitaire des Enfants Reine Fabiola (HUDERF), Brussels, Belgium & Institut de mucoviscidose de l’université libre de Bruxelles (ULB), hôpital universitaire des enfants Reine Fabiola - ULB, Brussels, Belgium.
Christianne Knoop, Institut de mucoviscidose de l’université libre de Bruxelles (ULB), hôpital universitaire Erasme – ULB, Brussels, Belgium.
Vicky Nowé, Department of Pulmonology, GZA Sint-Vincentius Hospital, Antwerp, Belgium.
Jessica Pirson, Service de Pneumologie, CHR Citadelle, Liège, Belgium.
Matthieu Thimmesch, Service de Pédiatrie, CHC Clinique du MontLégia, Liège, Belgium.
Eva Van Braeckel, Cystic Fibrosis Reference Centre, Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium & Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
Kim Van Hoorenbeek, Department of Pediatrics, Antwerp University Hospital, Edegem, Belgium.
Eef Vanderhelst, Respiratory Division, University Hospital UZ Brussel, Brussels, Belgium.

France

Tania Pressler, Rigshospitalet, Copenhagen Cystic Fibrosis Centre, Copenhagen, Denmark.

Carole Bailly Piccini, Centre Hospitalier Universitaire de Reims, Reims, France.
Chantal Belleguic, Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou, Rennes, France.
Tiphaine Bihouee, Centre Hospitalier Universitaire de Nantes, Nantes, France.
Yves Billon, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.
Stéphanie Bui, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France.
Boubou Camara, Centre Hospitalier Universitaire de Grenoble, La Tronche, France.
Marie-Christine Cheraud, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand France.
Raphael Chiron, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
Emmanuelle Coirier Duet, Centre Hospitalier de Versailles, Le Chesnay-Rocquencourt, France.
Laurence Cosson, Centre Hospitalier Régional Universitaire de Tours - Clocheville Hospital, Tours, France.
Marie-Laure Dalphin, Centre hospitalier universitaire de Besançon, Besançon, France.
Isabelle Danner Boucher, Centre Hospitalier universitaire de Nantes, Nantes, France.
Sandrine De Miranda, Hôpital Foch, Suresnes, France.
Eric Deneuville, Centre Hospitalier Universitaire de Rennes - Hôpital Sud, Rennes, France.
Jean-Christophe Dubus, Hôpitaux Universitaires de Marseille, Marseille, France.
Isabelle Durieu, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.
France

Angers, Vannes, Dunkerque, Besançon, Marseille, France

Gauthe, French, Centre Hospitalier Universitaire de Dijon Bourgogne, Dijon, France

Kanaan Reem, AP-HP Hôpital Cochin, Paris, France

Romain Kessler, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Jeanne Languedoc, Centre Hospitalier Universitaire de Limoges, Limoges, France

Muriel Laurans, Centre Hospitalier Universitaire de Caen, Caen, France

Sylvie Leroy, Centre Hospitalier Universitaire de Nice, Nice, France

Cathie Llerena, Centre Hospitalier Universitaire de Grenoble, La Tronche, France

Julie Macey, Centre Hospitalier Universitaire de Bordeaux - Hôpital Haut-Lévêque, Pessac, France

Julie Manikkin, Centre Hospitalier Régional Universitaire de Tours - Bretonneau, Tours, France

Christophe Marguet, Centre Hospitalier Universitaire de Rouen, Rouen, France

Clémence Martin, AP-HP Hôpital Cochin, Paris, France

Laurent Mely, Hospices Civils de Lyon - Hôpital Renée Sabran, Giens-Hyères, France

Marie Mittane, Centre Hospitalier Universitaire de Toulouse - Hôpital des Enfants, Toulouse, France

Marlène Murris-Espin, Centre Hospitalier Universitaire de Toulouse - Hôpital Larrey, Toulouse, France

Caroline Perisson, Centre Hospitalier Universitaire de La Réunion - sites Sud, Saint-Pierre, France

Anne Prevotat, Centre Hospitalier Universitaire de Lille, Lille, France

Sophie Ramel, Fondation ILYDS, Roscoff, France

Cynthia Rames, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France

Philippe Reix, Hospices Civils de Lyon, Hôpital Femme Mère Enfant, Bron, France

Marine Revillon, Centre Hospitalier Universitaire de Lille, Lille, France

Martine Reynaud-Gaubert, Hôpitaux Universitaires de Marseille, Marseille, France

Bénédicte Richaud-Thiriez, Centre hospitalier universitaire de Besançon, Besançon, France

Jean-Luc Rittie, Centre Hospitalier Universitaire de La Réunion - site Felix Guyon, Saint-Denis, France

Manuela Scalbert-Dujardin, Centre Hospitalier Dunkerque, Dunkerque, France

Isabelle Sermet-Gaudelus, AP-HP - Hôpital Necker Enfants malades, Paris, France

Véronique Sorni, Centre hospitalier Bretagne-Atlantique, Vannes, France

Aurélie Tatopoulos, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France

Guillaume Thouvenin, AP-HP Hôpital Armand-Trousseau, Paris, France

Françoise Troussier, Centre hospitalier universitaire d'Angers, Angers, France

Laurence Weiss, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Nathalie Wizla, Centre Hospitalier Universitaire de Lille, Lille, France

Germany

Eva-Susanne Behl, Klinikum Westbrandenburg, Klinik für Kinder- und Jugendmedizin, Potsdam, Germany

Martin Claßen, Klinikverbund Bremen gGmbH, Klinikum Links der Weser, Christiane Herzog-Ambulanze für Mukoviszidose, Bremen, Germany

Ute Graepler-Mainka, Department of General Pediatrics, Hematology and Oncology, Children’s Hospital, Eberhard-Karls-University, Tübingen, Germany

Birte Kinder, Dietrich Bonhoeffer Klinikum Neubrandenburg, Klinik für Kinder- und Jugendmedizin, Neubrandenburg, Germany

Holger Köster, Klinikum Oldenburg, Oldenburg, Germany

Jochen Mainz, Brandenburg Medical School (MHB), University, Klinikum Westbrandenburg, Brandenburg an der Havel, Germany

Angelika Mayer, Robert-Busch-Krankenhaus, Klinik Schillerhöhe, Pneumologie, Gerlingen, Germany

Susanne Naehrig, Medizinische Klinik V (Pneumology), LMU University of Munich, Pneumology, Medizinische Klinik Innenstadt, University of Munich, Munich, Germany

Thomas Nüßein, Gemeinschaftsklinikum Mittelrhein - Klinik für Kinder- und Jugendmedizin, Koblenz, Koblenz, Germany

Markus Rose, Klinikum Stuttgart, Oljahospital- Pediatric Pulmonology, Stuttgart, Germany

Josef Rosennecker, Fachkliniken Wangen, Wangen, Germany

Anette Scharschinger, Paediatric and Adolescent Medicine, University Medical Center Augsburg, Augsburg, Germany

Christian Schropp, Children's Hospital Dritter Orden, Passau, Germany

Carsten Schwarz, Department of Pediatric Pneumology, Immunology and Intensive Care Medicine, Cystic Fibrosis Center, Charité - Universitätsmedizin Berlin, Berlin, Germany

Simone Stolz, Klinik für Kinder- und Jugendmedizin, Carl-Thiem-Klinikum gGmbH, Cottbus, Germany

Wolfgang Thomas, Klinikum Mutterhaus der Borromäerinnen, Kinder- und Jugendmedizin, Trier, Germany

Sabine Wege, Department of Pneumology and Critical Care Medicine, Thoraxklinik at the University Hospital Heidelberg, Heidelberg, Germany

Britta Welzenbach, Josefuseum hospital for children and adolescents, Augsburg, Germany

Bettina Wollschläger, Martin-Luther-University Halle, Clinic for Internal Medicine, Halle, Germany

Greece

Filia Diamantina, Sismanoglio General Hospital of Attica, Adult Cystic Fibrosis Unit, Athens, Greece

Ireland

Barry J. Plant, University College Cork, Cork, Ireland

Cedric Gunaratnam, Beaumont Hospital, Dublin, Ireland

Italy

Annalisa Amato and Gianluca Ferrari, technical board of ICFR, Italian Cystic Fibrosis Ligue, Rome, Italy

Carlo Castellani and Rosaria Casiaro, CF Referral Center Liguria Region, IRCCS Istituto Giannina Gaslini Genova, Italy

Marco Cipolli and Francesca Lucca, CF Referral Center Veneto Region, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy

Valeria Daccò, Vanessa Gagliano and Giovanna Pizzamiglio, CF Referral Center Lombardia Region, Fondazione IRCCS Ca Granda - Ospedale Maggiore Policlinico, Milan, Italy
Spain

Elisabetta Bignamini and Anna Folino, CF Referral Center Piemonte and Valle D’Aosta Regions, Ospedale Infantile Regina Margherita – Sant’ Anna, Torino, Italy
Massimo Maschio, CF Referral Center Friuli-Venezia Giulia Region, IRCCS Materno Infantile Burlo Garofolo, Trieste, Italy
Mirco Ros, Veneto Region CF Support Center of Treviso, Ospedale Ca’ Foncello, Treviso Italy
Barbara Messore, Adult CF Centre Torino, Pulmonology Dept, Azienda Ospedaliero Universitaria San Luigi Gonzaga, Orbassano, Italy
Piercarlo Poli, Department of Pediatrics, Regional support Centre for Cystic Fibrosis, Children’s Hospital – ASST Spedali Civili P.z.le Spedali Civili, University of Brescia, Brescia, Italy
Stefano Pantano, CF Referral Center Abruzzi and Molise Region, Teramo, Italy
Fiorella Battistini and Valentina Donati, CF Referral Center Emilia-Romagna Region, Cesena, Italy
Valeria Mencarini and Nicola Palladino, CF Referral Center Umbria Region, Gubbio, Italy
Giuseppe Cimino, CF Referral Center Lazio Region, Rome, Italy
Valeria Raia and Caterina Laezza, CF Pediatric Referral Center Campania Region, Naples, Italy
Pamela Vitullo, CF Support Center, Puglia Region, Cerignola, Italy
Salvatore Leonardi and Novella Rotolo, CF Support Center, Sicily Region, Catania, Italy
Giovanna Pisi, Cinzia Spaggiari, CF Referral Center, Emilia-Romagna Region, Parma, Italy
Vincenzo Carnovale, Adult CF Referral Center, Campania Region, Naples, Italy
Maria Cristina Lucanto and Ester Quattromano, CF Referral Center, Sicily Region, Messina, Italy
Antonio Manca and Giuseppina Leonetti, CF Referral Center, Puglia Region, Bari, Italy
Mirella Collura and Francesca Ficili, CF Referral Center, Sicily Region, Palermo, Italy
Vincenzina Lucidi, Federico Alghisi, Fabiana Ciciriello and Fabio Majo, CF UOC, Paediatric Hospital “Bambino Gesù”, Rome, Italy

Luxembourg

Hélène De la Barrière, Department of Pulmonology, Hôpitaux Robert Schuman, Luxembourg, Luxembourg

Russia

Evgeniya Boitsova, Department of propaedeutics of children’s diseases. Federal state budgetary scientific institution of higher education “Saint Petersburg state pediatric medical University” of the Russian Federation Ministry of Health, Saint Petersburg, Russia
Yuliya Gorinova, National Medical Research Center for Children’s Health, Moscow, Russia
Stanislav Krasovskiy, Laboratory of cystic fibrosis, Scientific Research Institute of Pulmonology of the Federal Medical and Biological Agency of Russia, Moscow, Russia
Maria Mukhina, Medical and genetic Department, cystic fibrosis office of the State budgetary healthcare institution “Morozovskaya Children’s Municipal Clinical Hospital” Moscow, Russia
Victoria Sherman, The scientific and clinical Department of cystic fibrosis, “Research Centre for Medical Genetics”, Moscow, Russia

Spain

Antonio Alvarez Fernández, Hospital Universitario Vall d’Hebron, Adult Cystic Fibrosis unit, Barcelona, Spain
Isodoro Cortell-Aznar, Hospital Universitario y Politécnico La Fe, Unidad de Trasplante Pulmonar y Fibrosis Quística, Valencia, Spain
Layla Diab Cáceres, Hospital 12 de Octubre, Unidad de Fibrosis Quística, Madrid, Spain
Sílvia Gartner, Hospital Vall d’Hebron, Unidad Fibrosis Quística y Neumología Pediátrica, Barcelona, Spain
Rosa María Girón-Moreno, Hospital Universitario La Princesa, Neumología Adultos, Madrid, Spain
Carlos Peñalver Mellado, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
Rosa Nieto-Royo, Hospital Universitario de Ramón y Cajal, Unidad de Fibrosis Quística, Madrid, Spain
Concepción Prados-Sanchez, Hospital Universitario La Paz, Unidad de Fibrosis Quística Adultos, Servicio de Neumología, Madrid, Spain
Isabel Ramos Cancelo, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
Marta Ruiz de Valbuena, Hospital Infantil La Paz, Sección de Neumología Pediátrica, Unidad de Fibrosis Quística Pediátrica, Madrid, Spain

Sweden

Stefanie Diemer, Lunds university hospital, Sweden
Marita Gilljam, Gothenburg CF center, Sahlgrenska University Hospital, Sweden
Christina Krantz, Department of Women’s and Children’s Health, Research group; Paediatric Inflammation, Metabolism and Child Health Research, Uppsala University, Uppsala, Sweden
Ulrika Lindberg, Department of Respiratory Medicine and Allergology, Lund CF center, Skane University Hospital, Lund, Sweden

Switzerland

Christian Clarenbach, Universitätsspital Zürich, Klinik für Pneumologie, Adultes CF Zentrum, Zürich, Switzerland
Reta Fischer, Lindenholshofspital Quartier Bleu, Bern, Switzerland
Isabelle Rochat, Centre Hospitalier Universitaire Vaudois (CHUV), Département femme-mère-enfant, Service de pédiatrie, Unité de pneumologie et mucoviscidose pédiatrique, Lausanne, Switzerland

Ukraine

Lyudmyla Bober, Western Ukrainian Specialised Children’s Medical Centre, Lviv, Ukraine

Author Statement

Nachrich Lutz: Conceptualization, Methodology, Resources, Writing - Review & Editing, Project administration, Supervision, Funding acquisition. Orenti Annalisa: Conceptualization, Methodology, Formal analysis, Data Curation, Writing - Review & Editing, Project administration. Dunley Fiona: Conceptualization, Writing - Original Draft, Writing - Review & Editing, Project administration. Kasmi Irena: Resources, Writing - Review & Editing. Harutyunyan Satenik: Resources, Writing - Review & Editing. Pfleger Andreas: Resources, Writing - Review & Editing. Bobrovnychiy Vladimir: Resources, Writing - Review & Editing. Keegan Svetlana: Resources, Writing - Review & Editing. Danelau Geraldine: Resources, Writing - Review & Editing. Petrovka Guergana: Resources, Writing - Review & Editing. Bugaev Vukic Andreja: Resources, Writing - Review & Editing. Tjesic Drinkovic Duksa: Resources, Writing - Review & Editing. Yiallourova Panayiotis: Resources, Writing - Review & Editing. Drevinek Pavel: Resources, Writing - Review & Editing.
Declaration of Competing Interest

Dr. Naehrlich reports that he has received institutional fees for site participation in clinical trials from Vertex Pharmaceuticals and Boehringer Ingelheim; Dr. Orenti has nothing to disclose; Dr. Dunlevy reports institutional grants from Chiesi, during the conduct of the study; Dr. Kasmi has nothing to disclose; Dr. Harutyunyan has nothing to disclose; Dr. Pfleger has nothing to disclose; Dr. Bövronich has nothing to disclose; Dr. Keegan has nothing to disclose; Dr. Deneau has nothing to disclose; Dr. Petrova has nothing to disclose; Dr. Bambir has nothing to disclose; Dr. Vukič-Dugac has nothing to disclose; Dr. Tjekić-Drinković has nothing to disclose; Dr. Yiállouros has nothing to disclose; Dr. Drevinek reports personal fees from Vertex Pharmaceuticals, outside the submitted work; Prof. Milan Macek reports grants from Vertex Pharmaceuticals, outside the submitted work; Dr. Olesen has nothing to disclose; Dr. Hatzigiorou has nothing to disclose; Dr. Berezowska has nothing to disclose; Dr. Virta has nothing to disclose; Dr. Tješić has nothing to disclose; Dr. Bakkeheim, outside the submitted work; Mrs. Bilkova has nothing to disclose; Dr. Olesen has nothing to disclose; Dr. Bureghin has nothing to disclose; Ms. Lemmonier has nothing to disclose; Dr. Parulava has nothing to disclose; Dr. Hatzigiorou has nothing to disclose; Dr. Diamantna has nothing to disclose; Dr. Parniczky has nothing to disclose; G. Fletcher has nothing to disclose; Prof. McKone reports travel support from A Menarini, speaker fees from Roche Pharmaceuticals, consultancy fees from Insmed, consultancy fees from Janssen Pharmaceuticals, grants to institution and consultancy fees from Vertex, outside the submitted work; Dr. Mei-Zahav has nothing to disclose; Dr. Pando has nothing to disclose; Dr. Salvatore has nothing to disclose; Dr. Colombo has nothing to disclose; Dr. Aleksejeva has nothing to disclose; Dr. Malakauskas has nothing to disclose; Dr. Schessler has nothing to disclose; Dr. Fustik has nothing to disclose; Dr. Turcu has nothing to disclose; V. Gulmans has nothing to disclose; D. Zomer van Ommen has nothing to disclose; Dr. Wathne has nothing to disclose; Dr. Bakkeheim, outside the submitted work; Dr. Perek has nothing to disclose; Dr. Kondratjeva has nothing to disclose; Dr. Amelina has nothing to disclose; Dr. Zhekaite has nothing to disclose; Dr. Pop has nothing to disclose; Dr. Pop has nothing to disclose; Dr. O. Simonova has nothing to disclose; Dr. Krasnyk has nothing to disclose; Dr. Rodgers has nothing to disclose; Dr. Doskocil has nothing to disclose; Dr. Pekcan has nothing to disclose; Dr. Makukh has nothing to disclose; Dr. Brownlee has nothing to disclose; Ms. Cosgriff has nothing to disclose; Ms. McClenaghan has nothing to disclose; Dr. Carr reports personal fees from Chiesi Pharmaceuticals, personal fees and non-financial support from Vertex, personal fees from Zambon, personal fees from Insmed, outside the submitted work; Dr. Lammertyn has nothing to disclose; Dr. Zolin has nothing to disclose; Ms. Fox reports grants from ECFS, during the conduct of the study; Mr Krasnyk has nothing to disclose; Mrs. Van Rens has nothing to disclose; Dr. van Koningsbruggen-Rietschel reports grants and personal fees from Algipharma (HORIZON2020), personal fees from Deutsches Zentrum für Infektionsforschung, personal fees from Antabio, personal fees from Proteostasis, personal fees from Roche, personal fees from Vertex, outside the submitted work; Dr. Jung reports grants from Chiesi Pharmaceuticals, during the conduct of the study.

Acknowledgements

We thank the people with CF, and their families, for consenting to their data being included in the ECFSPR. We thank the centers and individual country representatives for allowing the use of the anonymized patient data.

This work was supported by an unrestricted grant from Chiesi Farmaceutici SpA, Parma, Italy. The funder had no role in the design, conduct or reporting of this study.

Datasets for the general population were provided by the European Centre for Disease Prevention and Control (ECDC) based on data provided by WHO and Ministries of Health from the affected countries. The views and opinions of the authors expressed herein
do not necessarily state or reflect those of the ECDC. The accuracy of the authors’ statistical analysis and the findings they report are not the responsibility of ECDC. ECDC is not responsible for conclusions or opinions drawn from the data provided. ECDC is not responsible for the correctness of the data and for data management, data merging and data collation after provision of the data. ECDC shall not be held liable for improper or incorrect use of the data.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jcf.2021.03.017.

References

[1] Dorjee K, Kim H, Bonomo E, Dolma R. Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients. PLoS One 2020;15:e0243191. doi:10.1371/journal.pone.0243191.
[2] Kedroski MR, Bomberger JM. Viral-Bacterial Co-Infections in the Cystic Fibrosis Respiratory Tract. Front Immunol 2018;9:3067. doi:10.3389/fimmu.2018.03067.
[3] Viviani L, Assael BM, Kereen E, group EHNs. Impact of the A (H1N1) pandemic influenza (season 2009-2010) on patients with cystic fibrosis. J Cyst Fibros 2011;10:370–6. doi:10.1016/j.jcf.2011.06.004.
[4] PinarSenkalF,BismanlarEyubogluT,AstlianAT,RamasiiCursoryT,SoyasA5,YaparD,e.a.EffectoftheCOVID-19pandemiconanxietyamongchildrenwithcysticfibrosisandtheirmothers. Pediatr Pulmonol 2020;55:2128–34. doi:10.1002/ppul.24900.
[5] Corvol H, de Miranda S, Lemonnier L, Kengang A, Reynaud Gaubert M, Chiron R, et al. First Wave of COVID-19 in French Patients with Cystic Fibrosis. J Clin Med 2020;9:3624. doi:10.3390/jcm9113624.
[6] Cosgriff R, Ahern S, Bell SC, Brownlee K, Burgel PR, Byrne C, et al. A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. J Cyst Fibros 2020;19:355–8. doi:10.1016/j.jcf.2020.04.012.
[7] McLennahan E, Cosgriff R, Brownlee K, Ahern S, Burgel PR, Byrne CA, et al. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. J Cyst Fibros 2020;19:868–71. doi:10.1016/j.jcf.2020.10.003.
[8] Bain R, Cosgriff R, Zampoli M, Elbert A, Burgel PR, Carr SB, et al. Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study. J Cyst Fibros 2021;20:25–30. doi:10.1016/j.jcf.2020.11.021.
[9] World Health Organization. Public health surveillance for COVID-19.2020. https://www.who.int/publications/i/item/who-2019-ncoov-surveillance-guidance-2020.7 Date accessed: 23 November 2020.
[10] World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases.2020. https://www.who.int/publications/i/item/10665-331501. Date accessed: 23 November 2020.
[11] World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as a death of cause.2020. https://www.who.int/classifications/icd/guidelines_cause_death_COVID-19.pdf?ua=1. Date accessed: 23 November 2020.
[12] ZolinaA, OrentiaA, NaehrlichI, JungA, van Rens J. ECFS Patient Registry Annual Report 2018.2020. https://www.ecfs.eu/projects/ecfs-patient-registry/annual-reports.
[13] Viviani L, Zolina A, Mehta A, Olesen HV. The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry. Orphanet J Rare Dis 2014;9:81. doi:10.1186/1747-1719-9-81.
[14] Dataset. European Centre for Disease Control. Daily number of new reported cases of COVID-19 by country worldwide.2020. https://www.ecdc.europa.eu/en/publications-data/download-today-data-geographic-distribution-covid-19-cases-worldwide. Date accessed: 06 Dec 2020.
[15] Dataset. European Centre for Disease Control. Data on hospital and ICU admission rates and current occupancy for COVID-19.2020. https://www.ecdc.europa.eu/en/publications-data/download-data-hospital-and-icu-admission-rates-and-current-occupancy-covid-19. Date accessed: 06 Dec 2020.